Cat. No.: HY-117025

Manzamine A

(Synonyms: Keramamine A)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1.

For research use only. We do not sell to patients.

Purity: 98.2%
CAS No.: 104196-68-1
Formula: C₃₆H₄₄N₄O
Molecular Weight:548.76

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Manzamine A Chemical Structure

CAS No.: 104196-68-1

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Publications Citing Use of MedChemExpress (MCE) Manzamine A

Customer Validation & Images

Cell Proliferation/Viability Assay

Cell Proliferation/Viability Assay
Cell Proliferation/Viability Assay

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]^[3]

Plasmodium

GSK-3β

10.2 μM (IC₅₀)

CDK5

1.5 μM (IC₅₀)

vacuolar ATPases

Malaria

HSV-1

All GSK-3 Isoforms :

All CDK Isoforms :

All Parasite Isoforms :

All HSV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	1.3 μg/mL Compound: manzamine A	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 8350092]
A549	IC₅₀	2.3 μM Compound: 3	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	[PMID: 27650927]
A549	IC₅₀	5.8 μM Compound: Manzamine A	Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34536668]
C-33-A	IC₅₀	1.6 μM Compound: 1	Antiproliferative activity against human C33A cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human C33A cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 32022559]
C-33-A	IC₅₀	2.1 μM Compound: 1	Antiproliferative activity against human C33A cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human C33A cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	[PMID: 32022559]
C-33-A	IC₅₀	5.2 μM Compound: 1	Antiproliferative activity against human C33A cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay Antiproliferative activity against human C33A cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay	[PMID: 32022559]
Ca-Ski	IC₅₀	19.9 μM Compound: 1	Antiproliferative activity against human CaSki cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human CaSki cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	[PMID: 32022559]
Ca-Ski	IC₅₀	33.6 μM Compound: 1	Antiproliferative activity against human CaSki cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay Antiproliferative activity against human CaSki cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay	[PMID: 32022559]
Ca-Ski	IC₅₀	9.4 μM Compound: 1	Antiproliferative activity against human CaSki cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human CaSki cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 32022559]
CHO	IC₅₀	4.8 μM Compound: 1	Non-competitive inhibition of human microsomal ACAT2 overexpressed in CHO cells using [14C]oleoyl-CoA as substrate assessed as formation of cholesteryl [14C]-oleate after 24 hrs Non-competitive inhibition of human microsomal ACAT2 overexpressed in CHO cells using [14C]oleoyl-CoA as substrate assessed as formation of cholesteryl [14C]-oleate after 24 hrs	[PMID: 23665143]
CHO	IC₅₀	6.2 μM Compound: 1	Non-competitive inhibition of human microsomal ACAT1 overexpressed in CHO cells using [14C]oleoyl-CoA as substrate assessed as formation of cholesteryl [14C]-oleate after 24 hrs Non-competitive inhibition of human microsomal ACAT1 overexpressed in CHO cells using [14C]oleoyl-CoA as substrate assessed as formation of cholesteryl [14C]-oleate after 24 hrs	[PMID: 23665143]
HeLa	IC₅₀	11.8 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay	[PMID: 32022559]
HeLa	IC₅₀	13 μM Compound: 1	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 24902064]
HeLa	IC₅₀	4 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	[PMID: 32022559]
HeLa	IC₅₀	5.3 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 32022559]
HT-29	IC₅₀	0.8 μg/mL Compound: manzamine A	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 8350092]
IMR-90	IC₅₀	6.8 μM Compound: 3	Cytotoxicity against human IMR90 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay Cytotoxicity against human IMR90 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	[PMID: 27650927]
K562	IC₅₀	5.2 μM Compound: Manzamine A	Cytotoxicity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34536668]
KB	IC₅₀	0.05 μg/mL Compound: 1	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 8158160]
L1210	IC₅₀	1.4 μg/mL Compound: 1	Cytotoxicity against mouse L1210 cells Cytotoxicity against mouse L1210 cells	[PMID: 9599281]
L5178Y	ED₅₀	1.8 μg/mL Compound: 7	Cytotoxicity against mouse L5178Y cells after 72 hrs by MTT assay Cytotoxicity against mouse L5178Y cells after 72 hrs by MTT assay	[PMID: 8946747]
LoVo	IC₅₀	0.15 μg/mL Compound: 1	Cytotoxicity against human LoVo cells Cytotoxicity against human LoVo cells	[PMID: 8158160]
Microglia	IC₅₀	<0.1 μM Compound: 1	Antineuroinflammatory activity in LPS-stimulated rat neonatal microglia assessed as inhibition of PMA-induced TXB2 production preincubated 15 mins prior to PMA challenge measured after 70 mins Antineuroinflammatory activity in LPS-stimulated rat neonatal microglia assessed as inhibition of PMA-induced TXB2 production preincubated 15 mins prior to PMA challenge measured after 70 mins	[PMID: 20017491]
Microglia	IC₅₀	<0.1 μM Compound: 3	Antiinflammatory activity in Escherichia coli lipopolysaccharide-activated rat neonatal microglia assessed as inhibition of eicosanoid thromboxane B2 Antiinflammatory activity in Escherichia coli lipopolysaccharide-activated rat neonatal microglia assessed as inhibition of eicosanoid thromboxane B2	[PMID: 18198837]
Microglia	IC₅₀	0.1 μM Compound: 1	Antineuroinflammatory activity in LPS-stimulated rat neonatal microglia assessed as inhibition of PMA-induced superoxide anion production preincubated 15 mins prior to PMA challenge measured after 70 mins Antineuroinflammatory activity in LPS-stimulated rat neonatal microglia assessed as inhibition of PMA-induced superoxide anion production preincubated 15 mins prior to PMA challenge measured after 70 mins	[PMID: 20017491]
NCI-H1299	IC₅₀	1.5 μM Compound: 3	Cytotoxicity against human NCI-H1299 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay Cytotoxicity against human NCI-H1299 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	[PMID: 27650927]
NCI-H1373	IC₅₀	2.1 μM Compound: 3	Cytotoxicity against human NCI-H1373 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay Cytotoxicity against human NCI-H1373 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	[PMID: 27650927]
NCI-H1993	IC₅₀	3.9 μM Compound: 3	Cytotoxicity against human NCI-H1993 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay Cytotoxicity against human NCI-H1993 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	[PMID: 27650927]
NCI-H2009	IC₅₀	1.6 μM Compound: 3	Cytotoxicity against human NCI-H2009 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay Cytotoxicity against human NCI-H2009 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	[PMID: 27650927]
NCI-H441	IC₅₀	1.1 μM Compound: 3	Cytotoxicity against human NCI-H441 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay Cytotoxicity against human NCI-H441 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	[PMID: 27650927]
P388	IC₅₀	0.07 μg/mL Compound: 1	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 8158160]
P388	IC₅₀	0.07 μg/mL Compound: 119	Cytotoxicity against mouse P388 cells assessed as cell growth inhibition Cytotoxicity against mouse P388 cells assessed as cell growth inhibition	[PMID: 34923389]
P388	IC₅₀	2.4 μg/mL Compound: manzamine A	Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 8350092]
Peritoneal macrophage cell	IC₅₀	6.2 μM Compound: 1	Antihyperlipidemic activity in apoE-deficient mouse peritoneal macrophages assessed as inhibition of acetylated LDL-induced [3H]-cholesterol ester accumulation after 24 hrs by radioscanner analysis in presence of [3H]-oleate-conjugated BSA Antihyperlipidemic activity in apoE-deficient mouse peritoneal macrophages assessed as inhibition of acetylated LDL-induced [3H]-cholesterol ester accumulation after 24 hrs by radioscanner analysis in presence of [3H]-oleate-conjugated BSA	[PMID: 23665143]
RAW264.7	IC₅₀	1.6 μM Compound: MA	Antiproliferative activity against mouse differentiated RAW 264.7 osteoclast cells assessed as reduction in cell viability incubated for 24 hrs by MTS viability assay Antiproliferative activity against mouse differentiated RAW 264.7 osteoclast cells assessed as reduction in cell viability incubated for 24 hrs by MTS viability assay	[PMID: 38383319]
RAW264.7	IC₅₀	1.9 μM Compound: MA	Antiproliferative activity against mouse RAW 264.7 preosteoclast cells assessed as reduction in cell viability incubated for 72 hrs by MTS viability assay Antiproliferative activity against mouse RAW 264.7 preosteoclast cells assessed as reduction in cell viability incubated for 72 hrs by MTS viability assay	[PMID: 38383319]
RAW264.7	IC₅₀	120 μM Compound: MA	Antiproliferative activity against mouse differentiated RAW 264.7 osteoclast cells assessed as reduction in cell viability incubated for 48 hrs by MTS viability assay Antiproliferative activity against mouse differentiated RAW 264.7 osteoclast cells assessed as reduction in cell viability incubated for 48 hrs by MTS viability assay	[PMID: 38383319]
RAW264.7	IC₅₀	2.2 μM Compound: MA	Antiproliferative activity against mouse RAW 264.7 preosteoclast cells assessed as reduction in cell viability incubated for 48 hrs by MTS viability assay Antiproliferative activity against mouse RAW 264.7 preosteoclast cells assessed as reduction in cell viability incubated for 48 hrs by MTS viability assay	[PMID: 38383319]
RAW264.7	IC₅₀	2.5 μM Compound: MA	Antiproliferative activity against mouse RAW 264.7 preosteoclast cells assessed as reduction in cell viability incubated for 24 hrs by MTS viability assay Antiproliferative activity against mouse RAW 264.7 preosteoclast cells assessed as reduction in cell viability incubated for 24 hrs by MTS viability assay	[PMID: 38383319]
RAW264.7	IC₅₀	47 μM Compound: MA	Antiproliferative activity against mouse differentiated RAW 264.7 osteoclast cells assessed as reduction in cell viability incubated for 72 hrs by MTS viability assay Antiproliferative activity against mouse differentiated RAW 264.7 osteoclast cells assessed as reduction in cell viability incubated for 72 hrs by MTS viability assay	[PMID: 38383319]
SiHa	IC₅₀	19.9 μM Compound: 1	Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay	[PMID: 32022559]
SiHa	IC₅₀	4.1 μM Compound: 1	Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 32022559]
SiHa	IC₅₀	9.9 μM Compound: 1	Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	[PMID: 32022559]
Vero	IC₅₀	0.2 μg/mL Compound: 1	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	[PMID: 20017491]
Vero	IC₅₀	0.501 μM Compound: 1	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	[PMID: 18595720]
Vero	IC₅₀	1.2 μg/mL Compound: 1	Cytotoxicity against african green monkey Vero cells by neutral red assay Cytotoxicity against african green monkey Vero cells by neutral red assay	[PMID: 16872140]
Vero	IC₅₀	11 nM Compound: 1	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs	[PMID: 19833520]
Vero	IC₅₀	8 nM Compound: 1	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs	[PMID: 19833520]

In Vitro

Manzamine A (5-50 µM, 18 h) decreases tau phosphorylation, measured with ELISA^[1].
Manzamine A (10 µM) inhibits yeast S. cerevisiae growth by 30%^[2].
Manzamine A displays a few enlarged vacuoles in yeast^[2].
Manzamine A (2.5-10 µM, 24 h) increases acidity in pancreatic cancer cells and non-malignant Vero cells^[2].
Manzamine A (1 µM, 24 h) inhibits HSV-1 infection in SIRC cells^[4].
Manzamine A shows antimalarial activity with an IC₅₀ of 8.0 nM (D6 clone) and 11 nM (W2 clone)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

SIRC cell
Concentration:

0.1, 0.5, 1, 2, 3, 5, and 10 µM
Incubation Time:

72 h
Result:

Inhibited SIRC cell viability with an IC₅₀ of 5.6 µM.

In Vivo

Manzamine A (50 and 100 mol/kg, p.o. or i.p.) inhibits the growth of the rodent malaria parasite Plasmodium berghei in infected mice^[6].
Manzamine A (8 mg/kg, i.p., daily for 8 consecutive days) prolongs the survival of SW mice to 20 days^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Plasmodium berghei in infected mice^[6]
Dosage:

50 or 100 mol/kg
Administration:

Intraperitoneal injection (i.p.) or oral administration (p.o.)
Result:

Inhibited the growth of the rodent malaria parasite Plasmodium berghei.
Prolonged the survival of highly parasitaemic mice.

Chemical Information

CAS No. 104196-68-1
Appearance Solid
Molecular Weight 548.76
Formula C₃₆H₄₄N₄O
Color White to off-white
SMILES

O[C@]1(CC/C=C\CCCC2)[C@@]3([H])[C@@](C[C@@]4([H])N3CCCC/C=C\4)(C[N@@]2CC5)[C@]5([H])C(C6=C(NC7=CC=CC=C87)C8=CC=N6)=C1
Synonyms

Keramamine A
Structure Classification
- Alkaloids
Initial Source
- Marine natural products
- Sponge
- Animals
Okinawan marine sponge
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All Cell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Mar Drugs

RIP1 Mediates Manzamine-A-Induced Secretory Autophagy in Breast Cancer. [Abstract]

2023 Feb 25;21(3):151. PMID: 36976201

Manzamine A purchased from MedChemExpress. Usage Cited in: Mar Drugs. 2023 Feb 25;21(3):151. [Abstract]

Manzamine A (MA; 0, 0.5, 1, 2, 4, 8 μM; 24 h) shows cytotoxic effects on MDA-MB-231 and MCF-7 cells but is non-toxic to normal breast epithelial MCF-10A cells in a dose-dependent manner.

Manzamine A purchased from MedChemExpress. Usage Cited in: Mar Drugs. 2023 Feb 25;21(3):151. [Abstract]

Manzamine A (MA) shows a long-term ability to inhibit both MCF-7 and MDA-MB-231 cells growth. The MA (0, 2, 4 μM; 24 h)-treated cells are seeded in 6-well plates and then cultured for 2 weeks.
bioRxiv

2026 Feb 25.

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (18.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8223 mL

9.1115 mL

18.2229 mL

5 mM

0.3645 mL

1.8223 mL

3.6446 mL

10 mM

0.1822 mL

0.9111 mL

1.8223 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (453 KB)
- English - EN (453 KB)
- Français - FR (453 KB)
- Deutsch - DE (453 KB)
- Norwegian - NO (453 KB)
- Español - ES (453 KB)
- Swedish - SV (453 KB)
- Italian - IT (453 KB)
- Portuguese - PT (453 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Hamann M, et al. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J Nat Prod. 2007;70(9):1397-1405. [Content Brief]

[2]. Kallifatidis G, et al. The marine natural product manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells [published correction appears in Mar Drugs. 2014;12(4):2305-7]. Mar Drugs. 2013;11(9):3500-3516. Published 2013 Sep 17. [Content Brief]

[3]. Winkler JD, et al. Antimalarial activity of a new family of analogues of manzamine A. Org Lett. 2006;8(12):2591-2594. [Content Brief]

[4]. Palem JR, et al. Manzamine A as a novel inhibitor of herpes simplex virus type-1 replication in cultured corneal cells. Planta Med. 2011;77(1):46-51. [Content Brief]

[5]. Wahba AE, et al. Structure-activity relationship studies of manzamine A: amidation of positions 6 and 8 of the beta-carboline moiety. Bioorg Med Chem. 2009 Nov 15;17(22):7775-82. [Content Brief]

[6]. Donia M, et al. Marine natural products and their potential applications as anti-infective agents. Lancet Infect Dis. 2003 Jun;3(6):338-48. [Content Brief]

[7]. El Sayed KA, et al. New manzamine alkaloids with potent activity against infectious diseases. J Am Chem Soc. 2001 Mar 7;123(9):1804-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8223 mL	9.1115 mL	18.2229 mL	45.5573 mL
	5 mM	0.3645 mL	1.8223 mL	3.6446 mL	9.1115 mL
	10 mM	0.1822 mL	0.9111 mL	1.8223 mL	4.5557 mL
	15 mM	0.1215 mL	0.6074 mL	1.2149 mL	3.0372 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Manzamine A

Publications Citing Use of MedChemExpress (MCE) Manzamine A

All GSK-3 Isoforms

All CDK Isoforms

All Parasite Isoforms

All HSV Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Manzamine A Related Classifications

Cat. No.: HY-117025